A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities
The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Activation of the Wnt/β-catenin signaling pathway occurs in several types of cancers and thus it is an attractive target for anticancer drug development. To identify compounds that inhibit this pathway, we screened a chemical library using a cell-based β-catenin/Tcf–responsive reporter. We identified FH535, a compound that suppresses both Wnt/β-catenin and peroxisome proliferator–activated receptor (PPAR) signaling. FH535 antagonizes both PPARγ and PPARδ ligand–dependent activation and shows structural similarity to GW9662, a known PPARγ antagonist. The effect of FH535 on β-catenin/Tcf activity is reduced in cells carrying a deletion of the PPARδ gene, as well as by the PPARγ agonist lysophosphatidic acid. Mechanistically, FH535 inhibits recruitment of the coactivators β-catenin and GRIP1 but not the corepressors NCoR and SMRT. Its repression of β-catenin recruitment, in comparison with GW9662, is linked to FH535′s unique capability to inhibit the Wnt/β-catenin signaling pathway. The antiproliferation effect of the compound observed on some transformed colon lung and liver cell lines is suggestive of its potential therapeutic value in the treatment of cancer. [Mol Cancer Ther 2008;7(3):521–9]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, niclosamide and two other β-catenin inhibitors (FH535 [116] and LF3 [117]) have been shown to downregulate MACC1-regulated S100A4 expression to decrease CRC propensity for metastatic progression [118].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [116]
Citations
Cites
1 retracted
Kodera, Y., Takeyama, K.-I., Murayama, A., Suzawa, M., Masuhiro, Y., & Kato, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000517200 · Cited by 187 · cited 3×
“For example, recruitment of GRIP1 and SRC1 coactivators by 15DPGJ2 is superior compared with troglitazone, an analogue of rosiglitazone (31).”
BackgroundRetractedWnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905 · cited 3×
“Plasmids The optimized and mutated Tcf-binding element–driven luciferase reporters (TOPFLASH, FOPFLASH) were provided by Dr. B. Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD).”
MethodInfluential15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Inhibition of Adipogenesis by Wnt Signaling
Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. L., & MacDougald, O. A. (2000) · Science · doi:10.1126/science.289.5481.950 · Cited by 1,874
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs
He, T.-C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,085
Wnt/β-catenin signaling in cancer stemness and malignant behavior
Fodde, R., & Brabletz, T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.007 · Cited by 785 · cited 1×
“Other intrinsic somatic mutations such as the oncogene Ras , as well as extrinsic factors like prostaglandins, are likely to play a rate-limiting role in Wnt signaling activation and contribute to the cancer development from the initial stem cell transformation to the metastasis stage (3).”
BackgroundLeesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 616 · cited 3×
“similar pattern of repressing coactivator recruitment, whereas allowing corepressor binding, was observed for GW9662 (26).”
Background
Cited by
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.001 · Cited by 294
Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
Liu, Y.-C., Yeh, C.-T., & Lin, K.-H. (2020) · Cells · doi:10.3390/cells9061331 · Cited by 253
“FH535 is another antagonist that inhibits the Wnt/β-catenin signaling pathway and peroxisome proliferatoractivator receptor (PPARγ and PPARδ) signaling [126].”
BackgroundDeshmukh, V., Hu, H., Barroga, C., Bossard, C., KC, S., Dellamary, L., Stewart, J., Chiu, K., Ibanez, M., Pedraza, M., et al. (2018) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2017.08.015 · Cited by 222
Exon 3 mutations of CTNNB1 drive tumorigenesis: a review
Gao, C., Wang, Y., Broaddus, R., Sun, L., Xue, F., & Zhang, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23695 · Cited by 224
Metadata
- Authors
- Handeli, S., & Simon, J. A.
- Affiliations
- Fred Hutch Cancer Center (US)
- ORCID
- Simon, Julian A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2008-03-01
- Volume
- 7
- Issue
- 3
- Pages
- 521-529
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2120269934
- Cited by
- 183
- References
- 46
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 11 · 2023: 6 · 2022: 7 · 2021: 13 · 2020: 11 · 2019: 13 · 2018: 17 · 2017: 17 · 2016: 16 · 2015: 12 · 2014: 13 · 2013: 12 · 2012: 12
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- FH535, Wnt/β-catenin signaling, PPARγ, PPARδ, small molecule inhibitors, GW9662, lysophosphatidic acid, coactivator recruitment, GRIP1, NCoR, SMRT, antiproliferative activity, anticancer drug development, colon cancer, lung cancer, liver cancer
- MeSH terms
- Base Sequence, Cell Line, Humans, Lysophospholipids, Sulfonamides, Signal Transduction, DNA Primers, PPAR delta, PPAR gamma, beta Catenin, TCF Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities. https://app.cochat.ai/papers/10.1158/1535-7163.mct-07-2063
- The paper
- Handeli, S., & Simon, J. A. (2008). A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-07-2063
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.